Ro Partners With Eli Lilly to Offer Zepbound, a Weight-Loss Medication, in Single-Dose Vials

Ro, a direct-to-consumer health and wellness company, has announced a partnership with Eli Lilly to provide discounted single-dose vials of the weight-loss medication Zepbound. Through this collaboration, Ro will utilize LillyDirect, Eli Lilly’s self-pay pharmacy channel, to deliver Zepbound to eligible patients with on-label prescriptions provided by Ro’s healthcare providers.
The partnership aims to make a more affordable version of the obesity treatment accessible to clinically eligible patients at self-pay prices. According to Ro, this new offering integrates diagnosis, treatment, and delivery into a seamless patient journey within a single application. This approach enables continuous care coordination, disease management, and personalized care plans tailored to each individual’s needs.

The single-dose vials of Zepbound are available in 2.5 mg and 5 mg doses, priced at $399 and $549 per month respectively for cash-paying customers without insurance coverage. This pricing aligns with Eli Lilly’s initiative launched in August, offering Zepbound doses through its LillyDirect platform at discounts exceeding 50% compared to the list price of other GLP-1 obesity treatments.
Ro introduced its weight-loss program in January 2023, giving members access to GLP-1 medications alongside personalized care plans, diagnostic testing with at-home sample collection, and one-on-one coaching from nurses. In May, Ro also launched an online supply tracker for GLP-1 medications, providing real-time updates on availability as an interactive tool for patients.
Zepbound was initially offered as a self-pay-only treatment for diabetes patients through LillyDirect. By integrating its offerings with Ro’s platform, patients can now access Zepbound without ever leaving the Ro app or their homes.